Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

208.06
+5.342.63%
Post-market: 208.060.00000.00%16:23 EDT
Volume:950.55K
Turnover:196.79M
Market Cap:13.05B
PE:-35.62
High:208.53
Open:203.94
Low:203.06
Close:202.72
52wk High:208.53
52wk Low:97.50
Shares:62.74M
Float Shares:60.79M
Volume Ratio:1.32
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8403
EPS(LYR):-5.8403
ROE:-8.47%
ROA:5.38%
PB:3.02
PE(LYR):-35.62

Loading ...

Earning Preview: Jazz Pharmaceuticals PLC Q1 revenue is expected to decrease by 0.67%, and institutional views are cautious to neutral

Earnings Agent
·
Apr 28

FOCUS-Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification

Reuters
·
Apr 30

TD Cowen Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Apr 27

Jazz Pharmaceuticals Announces FDA Acceptance And Priority Review Of Supplemental Biologics License Application For Ziihera®

Reuters
·
Apr 27

Jazz Pharma FDA wins priority review for Ziihera combos in first-line HER2+ GEA

Reuters
·
Apr 27

Jazz Pharmaceuticals Plc - FDA Sets Pdufa Date of August 25, 2026 for Ziihera Sbla

THOMSON REUTERS
·
Apr 27

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (Zanidatamab-Hrii) Combinations in First-Line Her2+ Locally Advanced or Metastatic Gea

THOMSON REUTERS
·
Apr 27

Jazz Pharmaceuticals Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Apr 22

Jazz Pharmaceuticals to report first-quarter results after market close

Reuters
·
Apr 22

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026

THOMSON REUTERS
·
Apr 22

Jazz spotlights Phase 3 HERIZON-GEA-01 PD-L1 subgroup data for Ziihera at ASCO

Reuters
·
Apr 22

Jazz Pharmaceuticals Is Maintained at Overweight by Barclays

Dow Jones
·
Apr 20

A Look At Jazz Pharmaceuticals (JAZZ) Valuation After New Neurology Data Plans At 2026 AAN Meeting

Simply Wall St.
·
Apr 16

Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says

MT Newswires Live
·
Apr 09

Jazz reports EpiCom analysis shows Epidiolex cuts behavioral problems in TSC seizures

Reuters
·
Apr 09

RBC Capital Remains a Buy on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Apr 08

Jazz director Bruce C. Cozadd disposes of Jazz Pharma shares worth $1.1 million

Reuters
·
Apr 04

Jazz Pharmaceuticals to present at Needham Virtual Healthcare Conference

Reuters
·
Apr 02

BRIEF-Pharma Mar Receives Positive Opinion From EMA Recommending Approval Of Zepzelca With Atezolizumab

Reuters
·
Mar 27

Pharma Mar - Phase 3 Imforte Trial, Sponsored by Roche in Collaboration With Jazz Pharmaceuticals

THOMSON REUTERS
·
Mar 27